The organ preservation market size is expected to advance at a CAGR of 7.7% during 2023–2030, to reach USD 442.6 million by 2030. This can be ascribed to the rapid increase in the number of organ failures across the globe, especially those with chronic kidney disorders and chronic conditions; the growing geriatric population; the rising disposable income in emerging economies; and the surging number of government awareness programs revolving around encouraging organ donations.
The rising number of R&D activities in the field of organ transplantation is leading to an increase in healthcare investments and in turn strengthening healthcare infrastructure to offer advanced healthcare facilities. For instance, according to the Centers for Medicare & Medicaid Services, national health expenditure rose by 2.7% to USD 4.3 trillion in 2021, or an average of about USD 12,914 per person, and accounted for 18.3% of GDP in the U.S. Also, modernized healthcare services will bring more donors and patients, which can help drive the demand for organ preservation solutions.
The applicability in the area of organ preservation in rectal cancer, head and neck cancer, rectal adenocarcinoma, laryngectomy, hypopharyngeal cancer, laryngeal cancer, allopurinol organ preservation, new organ preservation technique, organ preservation by vitrification, normothermic technique, and others, is increasing. In addition, the rising uses of organ preservation perfusion and solutions like HTK organ preservation solution, UW organ preservation solution, IGL-1 organ preservation solution, and organ preservation polymers play a crucial role to combat the surging frequency of disorders. Thus, these factors boost the market growth.
The liver category is expected to witness significant growth during the forecast period. This can be ascribed to the occurrence of cirrhosis leading to liver failure, and the liver is the second-most transplanted organ after the kidney. For instance, as per the UNOS report, in 2021, 9,236 liver transplantation surgeries were performed and 12,800 patients were added to the waiting list for a liver transplant.
Moreover, advancements in technologies and product launches by key industry players and a rise in liver transplant incidences are projected to boost the growth of the market in this category. For instance, in October 2021, Paragonix Technologies Inc. commercially launched LIVERguard Donor Liver Preservation System in both the U.S. and Europe; and in June 2022, it expanded the adoption of the preservation system at the 2022 American Transplant Congress in Boston, Massachusetts. This system offers a highly controlled, state-of-the-art environment for hypothermic liver preservation, together with real-time monitoring to protect a donor liver throughout the transplant journey from donation to transplantation.
Globally, the Asia-Pacific market is expected to grow at a CAGR of 8% during the forecast period. This can be attributed to the presence of key players, the rising population of the elderly, escalating per capita health expenditure, the booming incidence of sepsis, and the improving healthcare infrastructure in the region. Moreover, the rising number of kidney failures due to changing lifestyles, the increasing number of organ transplant centers and biobanks, and the surging burden of chronic diseases and inflammation are driving the regional market growth.
The most-significant organ preservation market players are XVIVO Perfusion AB, Paragonix Technologies Inc., Dr. Franz Köhler Chemie GmbH, OrganOx Limited, Bridge to Life Ltd., Artivion Inc., 21st Century Medicine Inc., TX Innovations, and Institut Georges Lopez.